Canada NewsWire MONTREAL, Feb. 13, 2025 MONTREAL, Feb. 13, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement ... the complexities of the complement pathways and selection of inhibition ...

Yet, data on the to which extent complement, and more specifically the alternative complement pathway, is activated in patients with carotid atherosclerosis and related to adverse outcome in these ...

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.

Figure 2. Complement during infection with a pathogen. The permanent activity of the alternative pathway allows it to immediately identify pathogens that are not specifically protected against ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

Is nuclear power or renewable energy the key to a zero-carbon future? Explore costs, risks, and global trends shaping the ...

Hydrogen is unlikely to become the sole energy carrier of the future, but it has an important role to play in a diversified ...

Despite a strong employment picture, TransUnion acknowledged some consumers are still struggling financially due to elevated ...